CRNX
Crinetics Pharmaceuticals, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 89 | -1 | 71.70M | $2.68B | +5 | −6 |
| Q1 2026 | 93 | +2 | 73.05M | $2.65B | +9 | −7 |
| Q4 2025 | 90 | 0 | 75.54M | $3.52B | n/a | n/a |
| Q3 2025 | 15 | 0 | 56.94M | $2.37B | n/a | n/a |
| Q2 2025 | 12 | 0 | 51.44M | $1.48B | +1 | −1 |
| Q1 2025 | 9 | -2 | 19.08M | $640.10M | +2 | −4 |
| Q4 2024 | 11 | -1 | 21.01M | $1.07B | n/a | −1 |
| Q3 2024 | 11 | -2 | 14.60M | $745.98M | n/a | −2 |
| Q2 2024 | 13 | n/a | 14.80M | $663.11M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 4.62M | n/a | $206.95M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 2 | T. Rowe Price ✦ | 4.41M | n/a | $197.37M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Point72 Asset Management ✦ | 2.78M | n/a | $124.55M | 0.4% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.68M | n/a | $75.19M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Fisher Asset Management ✦ | 444.67K | n/a | $19.92M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Duquesne Family Office ✦ | 309.00K | n/a | $13.84M | 0.5% | n/c | 1 | SEC ↗ |
| 7 | Adage Capital Partners ✦ | 201.05K | n/a | $9.00M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Marshall Wace ✦ | 141.20K | n/a | $6.32M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Citadel Advisors ✦ | 121.88K | n/a | $5.46M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | Millennium Management ✦ | 43.18K | n/a | $1.93M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 39.57K | n/a | $1.77M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | Two Sigma Investments ✦ | 10.80K | n/a | $483,732 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 7.13K | n/a | $319,174 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 241 holders, 121.45M shares, $4.08B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.